Company

Giant Biogene

巨子生物

Giant Biogene (巨子生物, 02367.HK) is a Chinese leader in professional skin care products based on bioactive ingredients, and the first listed "collagen stock" on the Hong Kong Stock Exchange's main board, per Gaorong Ventures . The company pioneered and leads China's recombinant collagen industry, built around a synthetic biology platform integrating biotechnology, biochemistry, and bioengineering developed under core researcher Dr. Fan Daidi . It commercializes 33 types of recombinant collagen and rare ginsenosides, with flagship brands Comfy (可复美) and Collgene (可丽金) ranking among China's top four professional skin care brands by retail sales in 2021 . Revenue grew from RMB 957 million in 2019 to RMB 1.55 billion in 2021, with net profit reaching RMB 314 million in the first five months of 2022 . Gaorong Ventures participated in its only funding round in October 2021 before the November 2022 IPO . More recently, in 2024, Giant Biogene secured a national invention patent for recombinant human type XVII collagen, expanding its portfolio beyond types I and III into hair follicle repair applications .

AI-generated — may contain errors, please verify.

Giant BiogeneCompany
巨子生物
渲染中…
Mentioned in 7 articles

Coverage